Cargando…

Progression of Renal Dysfunction in Patients with Cardiovascular Disease

It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Yasunobu, Kiyosue, Arihiro, Takahashi, Masao, Satonaka, Hiroshi, Nagata, Daisuke, Sata, Masataka, Suzuki, Etsu, Nagai, Ryozo
Formato: Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780821/
https://www.ncbi.nlm.nih.gov/pubmed/19936196
http://dx.doi.org/10.2174/157340308785160543
_version_ 1782174529345290240
author Hirata, Yasunobu
Kiyosue, Arihiro
Takahashi, Masao
Satonaka, Hiroshi
Nagata, Daisuke
Sata, Masataka
Suzuki, Etsu
Nagai, Ryozo
author_facet Hirata, Yasunobu
Kiyosue, Arihiro
Takahashi, Masao
Satonaka, Hiroshi
Nagata, Daisuke
Sata, Masataka
Suzuki, Etsu
Nagai, Ryozo
author_sort Hirata, Yasunobu
collection PubMed
description It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors.
format Text
id pubmed-2780821
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Bentham Science Publishers Ltd.
record_format MEDLINE/PubMed
spelling pubmed-27808212009-11-23 Progression of Renal Dysfunction in Patients with Cardiovascular Disease Hirata, Yasunobu Kiyosue, Arihiro Takahashi, Masao Satonaka, Hiroshi Nagata, Daisuke Sata, Masataka Suzuki, Etsu Nagai, Ryozo Curr Cardiol Rev Article It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors. Bentham Science Publishers Ltd. 2008-08 /pmc/articles/PMC2780821/ /pubmed/19936196 http://dx.doi.org/10.2174/157340308785160543 Text en ©2008 Bentham Science Publishers Ltd. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Hirata, Yasunobu
Kiyosue, Arihiro
Takahashi, Masao
Satonaka, Hiroshi
Nagata, Daisuke
Sata, Masataka
Suzuki, Etsu
Nagai, Ryozo
Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title_full Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title_fullStr Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title_full_unstemmed Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title_short Progression of Renal Dysfunction in Patients with Cardiovascular Disease
title_sort progression of renal dysfunction in patients with cardiovascular disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780821/
https://www.ncbi.nlm.nih.gov/pubmed/19936196
http://dx.doi.org/10.2174/157340308785160543
work_keys_str_mv AT hiratayasunobu progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT kiyosuearihiro progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT takahashimasao progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT satonakahiroshi progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT nagatadaisuke progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT satamasataka progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT suzukietsu progressionofrenaldysfunctioninpatientswithcardiovasculardisease
AT nagairyozo progressionofrenaldysfunctioninpatientswithcardiovasculardisease